A new trading day began on Tuesday, with Mereo Biopharma Group Plc ADR (NASDAQ: MREO) stock price up 1.45% from the previous day of trading, before settling in for the closing price of $2.76. MREO’s price has ranged from $1.58 to $5.02 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 57.98%. With a float of $132.68 million, this company’s outstanding shares have now reached $159.00 million.
Let’s look at the performance matrix of the company that is accounted for 36 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mereo Biopharma Group Plc ADR (MREO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Mereo Biopharma Group Plc ADR is 16.55%, while institutional ownership is 60.80%. The most recent insider transaction that took place on Sep 13 ’24, was worth 253,454. In this transaction Chief Executive Officer of this company sold 60,046 shares at a rate of $4.22, taking the stock ownership to the 808,921 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Chief Executive Officer sold 28,611 for $4.47, making the entire transaction worth $127,968. This insider now owns 868,967 shares in total.
Mereo Biopharma Group Plc ADR (MREO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 57.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.31% during the next five years compared to 34.82% growth over the previous five years of trading.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
Here are Mereo Biopharma Group Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.31, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.04 in one year’s time.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) saw its 5-day average volume 1.07 million, a negative change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 81.51%. Additionally, its Average True Range was 0.15.
During the past 100 days, Mereo Biopharma Group Plc ADR’s (MREO) raw stochastic average was set at 72.84%, which indicates a significant decrease from 93.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.49% in the past 14 days, which was higher than the 69.20% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.38, while its 200-day Moving Average is $3.22. Nevertheless, the first resistance level for the watch stands at $2.83 in the near term. At $2.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.91. If the price goes on to break the first support level at $2.75, it is likely to go to the next support level at $2.71. Assuming the price breaks the second support level, the third support level stands at $2.67.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Key Stats
With a market capitalization of 445.20 million, the company has a total of 159,000K Shares Outstanding. Currently, annual sales are 0 K while annual income is -43,250 K. The company’s previous quarter sales were 0 K while its latest quarter income was -12,890 K.
